| Literature DB >> 26182238 |
Raffaella Soldi1, Stephen K Horrigan2, Marek W Cholody3, Janak Padia4, Venkataswamy Sorna1, Jared Bearss1, Glynn Gilcrease1, Kapil Bhalla5, Anupam Verma6, Hariprasad Vankayalapati1, Sunil Sharma1.
Abstract
The Wnt/β-catenin signaling pathway plays a vital role in cell growth, the regulation, cell development, and the differentiation of normal stem cells. Constitutive activation of the Wnt/β-catenin signaling pathway is found in many human cancers, and thus, it is an attractive target for anticancer therapy. Specific inhibitors of this pathway have been keenly researched and developed. Cell based screening of compounds library, hit-to-lead optimization, computational and structure-based design strategies resulted in the design and synthesis of a series of anthracene-9,10-dione dioxime series of compounds demonstrated potent inhibition of β-catenin in vitro (IC50 < 10 nM, 14) and the growth of several cancer cell lines. This article discusses the potential of inhibiting the Wnt/β-catenin signaling pathway as a therapeutic approach for cancer along with an overview of the development of specific inhibitors.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26182238 DOI: 10.1021/acs.jmedchem.5b00460
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446